MEIP - MEI Pharma Inc
Region: US
Website: https://www.meipharma.com/
Employees: 127
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.